Market Intelligence, Clinical Progress, and High-Purity Reagents for Pain, Dry Eye Disease, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TRPM8 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TRPM8 ECD-Fc Domain Protein (>95% purity, Endotoxin <1EU/ug) & Full-Length Lentiviral Expression System. Sequence Verified. HEK293 expressed for native glycosylation. | View TRPM8 Products |
| Gene Delivery | TRPM8 Premade Lentivirus Particles. Full-length ORF for stable cell line generation. Compatible with calcium flux and patch clamp assays. | View TRPM8 Products |
| Benchmark Ab | Anti-TRPM8 Recombinant Antibody. High purity (>95%), Endotoxin <1EU/ug. Validated for flow cytometry and surface expression. | View TRPM8 Products |
| Validator | TRPM8 siRNA Set. Three target-specific duplexes for knockdown verification and specificity controls. | View TRPM8 Products |
| TRPV1 | TRPV1 Channel Protein / Lentivirus. Essential counter-screening target for thermal sensing selectivity. | View TRPV1 Products |
| TRPA1 | TRPA1 Channel Protein / Lentivirus. Chemical irritant sensor for off-target liability assessment. | View TRPA1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cold-Activated Conformation Preservation | HEK293-expressed full-length lentivirus ensuring native tetrameric assembly and post-translational modifications for physiological cold activation. |
| TRP Channel Selectivity (TRPV1/TRPA1 off-target) | Sequence-verified homolog panels (TRPV1, TRPA1, TRPM3) with >95% purity for rigorous counter-screening. |
| Surface Expression & Membrane Localization | Anti-TRPM8 reference antibody validated for flow cytometry and surface staining. |
| False Positives in Calcium Flux / Patch Clamp | TRPM8 siRNA set included for specific knockdown and baseline signal calibration. |
Live TRPM8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TRPM8 therapeutics has shifted dramatically. Early systemic small-molecule antagonists (e.g., Pfizer PF-05105679, Amgen AMG 333) targeting neuropathic pain and migraine were halted due to on-target thermoregulatory side effects (core body temperature fluctuations and cold allodynia). The field has pivoted to localized and topical modalities. Leading the late-stage pipeline are topical TRPM8 agonists such as Alcon's AR-15512 (Phase 3 for Dry Eye Disease), which stimulates tear production and provides cooling analgesia without systemic exposure. In oncology, TRPM8 overexpression in castration-resistant prostate cancer (CRPC) has positioned it as a cell-surface biomarker for antibody-drug conjugates (ADCs) and peptide-based delivery systems. Future directions include peripherally restricted modulators, allosteric modulators with state-dependent binding, and combination therapies with opioid-sparing mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonists | Alcon (AR-15512), Aerie Pharmaceuticals | Dry Eye Disease, Ocular Pain | Functional calcium flux assay on stable cell lines with native tetrameric pore assembly |
| Small Molecule Antagonists | Pfizer, Amgen, Glenmark, Bayer (historical) | Neuropathic Pain, Migraine, Chronic Cough | Selectivity & counter-screening panel (TRPV1/TRPA1) to eliminate off-target hits |
| Topical Cooling Agents / Peripherally Restricted Modulators | Cosmos Pharmaceutical, Emerging biotech | Neuropathic Pain, Pruritus, Cold Allodynia | Reversible binding assay (SPR) using high-purity ECD proteins |
| Biologics / ADCs | Emerging biotech, NCI-sponsored labs | Castration-Resistant Prostate Cancer (CRPC) | Conformational epitope mapping with intact membrane protein lentivirus |
| Selective Modulators / Allosteric | Academic consortia | Cold Allodynia, Pain | Cross-reactivity panel (TRPV1/TRPA1/TRPM3) for off-target assessment |